Skip to Content

Join the 'Candida Infections' group to help and get support from people like you.

Candida Infections News

13 Cases of 'Superbug' Fungal Infection in U.S.

Posted 4 Nov 2016 by Drugs.com

FRIDAY, Nov. 4, 2016 – Federal health officials say 13 cases of a potentially deadly, drug-resistant fungal infection have been reported in the United States. Four of those cases ended in death, but health officials said it's not clear if the deaths were due to the infection or the patients' underlying health conditions. Candida auris fungal infection is emerging as a health threat worldwide, and it appears to spread in hospitals and other health care facilities, according to the U.S. Centers for Disease Control and Prevention. "We need to act now to better understand, contain and stop the spread of this drug-resistant fungus," CDC Director Dr. Tom Frieden said in an agency news release. "This is an emerging threat, and we need to protect vulnerable patients and others." Of the 13 U.S. cases reported between May 2013 and August 2016, seven are described in the CDC's Nov. 4 Morbidity ... Read more

Related support groups: Infections, Fluconazole, Diflucan, Lamisil, Nystatin, Terbinafine, Clotrimazole, Ketoconazole, Miconazole, Candida Infections, Griseofulvin, Nizoral, Itraconazole, Amphotericin B, Sporanox, Voriconazole, Gris-PEG, Hydroxypropyl Chitosan/terbinafine, Mycostatin, Nilstat

Skin Infections Common in High School Wrestlers, Study Finds

Posted 10 Feb 2016 by Drugs.com

WEDNESDAY, Feb. 10, 2016 – Wrestlers are much more likely to suffer skin infections than other U.S. high school athletes, new research shows. The study authors examined five years of data on skin infections among athletes in 22 high school sports. Nearly 74 percent of skin infections occurred among wrestlers, and just under 18 percent among football players, the investigators found. The actual rates of skin infections per 100,000 exposures (one athlete participating in one practice, competition or performance) were 28.5 among wrestlers and 2.3 among football players. Rates in most other sports were less than 1 per 100,000, and eight sports had none, according to the report. "Given the nature of the sport, it's not surprising that wrestlers suffer the most skin infections," study senior author Dr. Robert Dellavalle, an associate professor of dermatology at the University of Colorado ... Read more

Related support groups: Infections, Bacterial Infection, Bacterial Skin Infection, Fungal Infections, Tinea Corporis, Skin and Structure Infection, Candida Infections, Tinea Cruris, Tinea Pedis, Fungal Infection Prophylaxis, Fungal Infection Prevention

FDA Medwatch Alert: Noxafil (posaconazole): Drug Safety Communication - Dosing Errors when Switching between Different Oral Formulations; Label Changes Approved

Posted 4 Jan 2016 by Drugs.com

ISSUE: The FDA is cautioning that differences in dosing regimens between the two oral formulations of the antifungal Noxafil (posaconazole) have resulted in dosing errors.  To help prevent additional medication errors, the drug labels were revised to indicate that the two oral formulations cannot be directly substituted for each other but require a change in dose.  Direct mg for mg substitution of the two formulations can result in drug levels that are lower or higher than needed to effectively treat certain fungal infections.  Since the approval of Noxafil delayed-release tablets in November 2013, FDA received eleven reports of the wrong oral formulations being prescribed and/or dispensed to patients.  One case resulted in death, and an additional case resulted in hospitalization.  According to the reports, these outcomes were a result of health care professionals not knowing that the t ... Read more

Related support groups: Candida Infections, Aspergillosis - Invasive, Noxafil, Posaconazole

FDA Approves Merck’s Noxafil Delayed-Release Tablets

Posted 26 Nov 2013 by Drugs.com

WHITEHOUSE STATION, N.J., Nov. 26, 2013--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Noxafil (posaconazole) 100 mg delayed-release tablets. Noxafil delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Merck also markets Noxafil (40 mg/mL) oral suspension, which is dosed three times daily. Noxafil delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as ... Read more

Related support groups: Candida Infections, Candida, Aspergillosis, Noxafil, Posaconazole

Ask a Question

Further Information

Related Condition Support Groups

Systemic Candidiasis

Related Drug Support Groups

fluconazole, Diflucan, itraconazole, amphotericin b, Sporanox, voriconazole, AmBisome, amphotericin b lipid complex, Mycamine, view more... flucytosine, Vfend, Abelcet, Eraxis, Noxafil, Fungizone, Cancidas, micafungin, anidulafungin, amphotericin b liposomal, caspofungin, Onmel, Sporanox PulsePak, posaconazole, amphotericin b cholesteryl sulfate, Amphotec, Amphocin, Ancobon